Clinical trials: Difficile
Clostridium Difficile Associated Diarrhea (CDAD)
A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)
This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of surotomycin (CB-183,315) at ascending dose levels when given to healthy males and females.
- Trial name
- NCT02835105
- Testing
- Surotomycin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium…
- Trial name
- Clover (NCT03090191)
- Testing
- Clostridium difficile vaccine
- Where
- 426 sites in United States, Argentina and 21 more
- Volunteers
- 17,535 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Colitis
Phase I Trial of a Single Dose of CRS3123
Double-blind, randomized, placebo-controlled Phase I Trial to determine the safety and pharmokinetics of a single dose of CRS3123 in healthy adult volunteers.
- Trial name
- NCT01551004
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
This is a Phase I, single center, randomized, placebo-controlled, double-blind, multiple ascending dose study to evaluate the safety and tolerability of CRS3123, a methionyl-tRNA synthetase inhibitor.
- Trial name
- NCT02106338
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Colitis
Syndecan 1 as Biomarker for Inflammation
The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus…
- Trial name
- NCT02333526
- Where
- 2 sites in Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Helios Albert-Schweitzer-Klinik Northeim
Recurrent C. Difficile Associated Diarrhea
Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea
The objective of the study is to investigate the efficacy of fresh, frozen or lyophilized fecal microbiota transplantation (FMT) via colonoscopy in patients with recurrent C. difficile associated diarrhea (RCDAD).
- Trial name
- NCT02318992
- Testing
- Fecal Microbiota
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Clostridium Difficile Infections
Safety Registry of a Fecal Microbiota Transplant Cohort
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection.
- Trial name
- COSMIC-FMT (NCT06311006)
- Where
- France
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clostridium Difficile Associated Disease
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
This study will investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.
- Trial name
- NCT02117570
- Testing
- Clostridium difficile vaccine
- Where
- 12 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile
Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections
Background: There is an urgent need to develop new strategies to prevent Clostridium difficile infections (CDI). A recent study suggests that a novel infection control bundle (IC bundle) can lead to a significant decrease in the…
- Trial name
- EFFICACI (NCT03223415)
- Testing
- Detection and isolation of C. difficile carriers
- Where
- 5 sites in Canada
- Volunteers
- 4,138 people, healthy volunteers welcome
- Sponsor
- Yves Longtin
Clostridium Infections
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a…
- Trial name
- NCT04026009
- Testing
- C. difficile investigational vaccine based on the F2 antigen (GSK2904545A), C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
- Where
- Belgium
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Clostridium Difficile Infection
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan
The aim of the study is to evaluate a candidate C. difficile Toxoid Vaccine in the Japanese population. Primary objectives: To describe the safety profile of all subjects who receive at least 1 injection To describe the…
- Trial name
- NCT01896830
- Testing
- Clostridium difficile Toxoid Vaccine, 0.9% normal saline
- Where
- Japan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Oral Vaccination Against Clostridium Difficile Infection
This clinical study is conducted to assess the safety and immunogenicity of a Clostridium difficile vaccine (CDVAX) in healthy adult volunteers.
- Trial name
- CDVAX (NCT02991417)
- Testing
- CDVAX
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Simon M. Cutting
Clostridium Difficile Infection Recurrence
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in…
- Trial name
- NCT05606159
- Testing
- Bacillus velezensis DSM 33864
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novozymes A/S
Urinary Tract Infections
Evaluating UTI Diagnosis in Nursing Homes
This prospective, multicenter, comparative cohort observational study is to determine whether the use of Guidance® UTI Clinical Pathway, a standardized infrastructure for specimen collection and result delivery, compared with…
- Trial name
- NCT04815369
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Clostridium Difficile Infection
An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
An open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, A new vaccine against Clostridium Difficile (C. difficile), In healthy subjects
- Trial name
- NCT01296386
- Testing
- IC84
- Where
- 3 sites in Austria, Hungary
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Clostridium Difficile Associated Disease
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine.
- Trial name
- NCT03579459
- Testing
- Clostridium difficile vaccine
- Where
- 24 sites in United States
- Volunteers
- 1,317 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection
Pathogenic Mechanisms in C Diff Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut.
- Trial name
- NCT01930032
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
C. Difficile, C. Difficile Infection
Clostridioides Difficile Controlled Human Infection Model
This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea.
- Conditions
- C. Difficile, C. Difficile Infection, Controlled Human Infection
- Trial name
- CloDiCHI (NCT06702345)
- Testing
- encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Clostridioides Difficile Infection
Clostridioides Difficile Colonisation
This study will investigate experimental colonisation with non-toxigenic C.difficile (NTCD) in healthy volunteers. Main outcomes will be safety, tolerability, dose needed to obtain colonisation with NTCD to ultimately determine…
- Trial name
- CloDiCo (NCT05693077)
- Testing
- 10E4 NTCD spores, 10E7 NTCD spores, Vancomycin Oral Capsule
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center